- Home
- PET vs MIRM Comparison
PET vs MIRM Comparison
Compare PET & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PET
- MIRM
- Stock Information
- Founded
- PET 2015
- MIRM 2018
- Country
- PET United States
- MIRM United States
- Employees
- PET N/A
- MIRM N/A
- Industry
- PET EDP Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- PET Technology
- MIRM Health Care
- Exchange
- PET Nasdaq
- MIRM Nasdaq
- Market Cap
- PET N/A
- MIRM 1.9B
- IPO Year
- PET N/A
- MIRM 2019
- Fundamental
- Price
- PET $0.15
- MIRM $40.00
- Analyst Decision
- PET Strong Buy
- MIRM Strong Buy
- Analyst Count
- PET 5
- MIRM 11
- Target Price
- PET $4.90
- MIRM $58.55
- AVG Volume (30 Days)
- PET 9.7M
- MIRM 447.2K
- Earning Date
- PET 05-08-2025
- MIRM 05-07-2025
- Dividend Yield
- PET N/A
- MIRM N/A
- EPS Growth
- PET N/A
- MIRM N/A
- EPS
- PET N/A
- MIRM N/A
- Revenue
- PET $70,507,000.00
- MIRM $336,888,000.00
- Revenue This Year
- PET $7.87
- MIRM $29.51
- Revenue Next Year
- PET $122.23
- MIRM $20.27
- P/E Ratio
- PET N/A
- MIRM N/A
- Revenue Growth
- PET N/A
- MIRM 80.76
- 52 Week Low
- PET $0.08
- MIRM $23.14
- 52 Week High
- PET $2.47
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- PET 49.88
- MIRM 41.05
- Support Level
- PET $0.08
- MIRM $38.22
- Resistance Level
- PET $0.14
- MIRM $40.14
- Average True Range (ATR)
- PET 0.02
- MIRM 2.24
- MACD
- PET 0.00
- MIRM 0.07
- Stochastic Oscillator
- PET 68.58
- MIRM 48.50
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.